ORI exhibits dose‐ and time‐dependent inhibition of the cancerous cell growth and upregulation of apoptosis in blood cancer HPB‐ALL cells through the upregulation of the proapoptotic proteins BAX and BH3‐interacting domain death agonist (BID) and downregulation of BCL‐2 and BCL‐XL expression along with disruption of potential of mitochondrial membrane (ΔΨm) and the activation of caspase‐3 (Liu et al., 2006). The gene discussed is BCL2; the disease is acute lymphoblastic leukemia.